Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin
To assess the effect of baseline variables, including treatment, on clinical cure and survival rates in patients with Gram-positive, ventilator-associated pneumonia (VAP).
Retrospective analysis of two randomized, double-blind studies.
Multinational study with 134 sites.
544 patients with suspected Gram-positive VAP, including 264 with documented Gram-positive VAP and 91 with methicillin-resistant S. aureus (MRSA) VAP.
Linezolid 600 mg or vancomycin 1 g every 12 h for 7–21 days, each with aztreonam.
Measurements and results
Clinical cure rates assessed 12–28 days after the end of therapy and excluding indeterminate or missing outcomes significantly favored linezolid in the Gram-positive and MRSA subsets. Logistic regression showed that linezolid was an independent predictor of clinical cure with odds ratios of 1.8 for all patients, 2.4 for Gram-positive VAP, and 20.0 for MRSA VAP. Kaplan-Meier survival rates favored linezolid in the MRSA subset. Logistic regression showed that linezolid was an independent predictor of survival with odds ratios of 1.6 for all patients, 2.6 for Gram-positive VAP, and 4.6 for MRSA VAP.
Initial linezolid therapy was associated with significantly better clinical cure and survival rates than was initial vancomycin therapy in patients with MRSA VAP.
KeywordsLinezolid Vancomycin Gram-positive pneumonia Methicillin-resistant Staphylococcus aureus Mechanical ventilation Regression analysis
- 2.Dupont H, Mentec H, Sollet JP, Bleichner G (2001) Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 27:355–362Google Scholar
- 5.Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef M (2003) Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphyloccus aureus nosocomial pneumonia. Chest 2003 (in press)Google Scholar
- 7.Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, Falcone RE, Anholm JD, Paganin F, Fabian TC, Lilienthal F (2000) Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 161:753–762PubMedGoogle Scholar
- 9.Georges H, Leroy O, Alfandari S, Guery B, Roussel-Delvallez M, Dhennain C, Beaucaire G (1997) Pulmonary deposition of vancomycin in critically ill patients. Eur J Clin Microbial Infect Dis 16:385–388Google Scholar
- 12.Honeybourne D, Tobin C, Jevons G, Andrews A, Wise R (2002) Intrapulmonary penetration of linezolid. Chest 122 (4 Suppl):159S. AbstractGoogle Scholar
- 14.Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ (2000) Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 57 [Suppl 2]:S4–S9Google Scholar
- 15.Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D (2001) Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45:2460–2467CrossRefPubMedGoogle Scholar